Short answer
Edgewise Therapeutics, Inc. (EWTX) filed an 8-K current report with the SEC on June 1, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). $1.55B upfront cash sale of Sevasemten and Edgewise’s neuromuscular program to Servier, subject to closing conditions.
Edgewise Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $1.55B upfront cash sale of Sevasemten and Edgewise’s neuromuscular program to Servier, subject to closing conditions
- Additional milestones up to $1.1B tied to Becker and Duchenne approvals plus $550M annual U.S. net sales
- Transaction expected to close Q3 2026, pending Hart-Scott-Rodino clearance and other customary conditions
- Servier employment offers preserve continuity for employees supporting the transferred program
- Proceeds and program transfer materially reshape Edgewise’s portfolio and future revenue exposure to Sevasemten development outcomes
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Edgewise Therapeutics, Inc. 8-K filings
Get the next EWTX 8-K as it lands
Follow EWTX for push alerts, or ask the research agent what this filing means.